Actualités

Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.9%

U.S. lawmakers have opened national security investigations into Merck's clinical trial activities in China. The probes focus on trials conducted in politically sensitive regions, including Xinjiang, and at hospitals linked to the Chinese military. Key concerns include intellectual property protection, ethical oversight, and the handling of sensitive biotechnology data. Merck, listed as NYSE:MRK, is a large global pharmaceutical company with a heavy focus on prescription medicines,...

A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country’s military capabilities, according to a...

Merck's (MRK) upcoming phase 3 OptiTrop-Lung06 readout could establish SAC-TMT as a chemotherapy rep

A bipartisan House committee wants details on hundreds of clinical studies conducted at Chinese military facilities and in Xinjiang

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

AbbVie (ABBV) and Merck (MRK) are facing investigations by the China Select Committee of the US Hous

June 30 (Reuters) - A bipartisan group of U. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved in clinical trials conducted in China that helped fuel the communist country's military capability, according ‌to letters seen by Reuters.

AbbVie (ABBV) - a pharmaceutical company developing and selling specialized therapies - hit a 5-day winning streak, with cumulative gains over this period amounting to 17%. The company's market cap has surged by about $65 Bil over the last 5 days and currently stands at $448 Bil.

This pharma giant's recent run is grabbing headlines, but its long-term behavior tells a more interesting story about portfolio risk.

Moderna hit a 52-week high after it unveiled a strategy to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and AI-driven R&D.

According to the average brokerage recommendation (ABR), one should invest in Merck (MRK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Nasdaq 100 futures advanced more than 1% in premarket trade after tech stocks shed nearly 5% last week

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]

Wondering whether Merck at US$128.66 is still offering fair value, or if the recent run means you are paying too much for the stock? The share price moves have been strong, with Merck showing returns of 13.0% over 7 days, 7.0% over 30 days, 20.9% year to date and 68.1% over the past year, in addition to longer term returns of 22.3% over 3 years and 91.3% over 5 years. Recent headlines around Merck have kept the stock in focus and reinforced investor attention on its long term prospects and...

Merck (MRK) closed the most recent trading day at $128.66, moving +2.56% from the previous trading session.

Moderna shares were up more than 10% Friday after the biotech company revealed a new effort to make a treatment for autoimmune disorders and outlined several experimental drug projects that could help it diversify beyond Covid-19 vaccines in coming years.

Lilly, AbbVie and J&J extend winning streaks.

Bio-Techne stock rallies as Merck announces an agreement to acquire it for $73 per share. But is there any further upside left in TECH shares?

The company's post-Humira plan is working brilliantly, but a subtle shift in the growth rate of one of its two key drugs deserves a much closer look.

Shares of Moderna (NASDAQ:MRNA) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the mRNA pioneer. Intraday, MRNA stock hit a new 52-week high of $69.29. The rally easily outpaces peer vaccine makers. Merck (NYSE:MRK) stock is up 2% to $128, while Pfizer (NYSE:PFE) stock trades up 2% ... Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?

Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.

Merck KGaA (MKKGY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Gilead Sciences Inc. (NASDAQ:GILD) ranks among the best set-it-and-forget-it stocks to buy right now. Cantor Fitzgerald restated an Overweight rating and a $155 price target for Gilead Sciences Inc. (NASDAQ:GILD) on June 9, following the company’s clinical research findings. Gilead Sciences Inc. (NASDAQ:GILD), in collaboration with Merck, revealed solid top-line results from the phase 3 […]

Merck KGaA's agreement to buy Bio-Techne for $11.3 billion strengthens its hold in life sciences, especially drug discovery and gene therapy.

Bio-Techne Corp. (NASDAQ:TECH) is one of the 9 Stocks Winning by Double Digits. Bio-Techne rallied for a third straight day on Thursday, surging 20.08 percent to close at $70.70 apiece, as investors gobbled up shares following news that it is merging with pharmaceutical giant Merck for $11.3 billion. In a statement, Bio-Techne Corp. (NASDAQ:TECH) said […]

Find insight on Merck KGaA’s deal to buy Bio-Techne, GSK and more in the latest Market Talks covering the Health Care sector.

By Karen Roman Candel Therapeutics, Inc. (Nasdaq: CADL) said it appointed Mark Sims as Chief Commercial Officer effective July 6, 2026, having previously served at AstraZeneca as Vice President and Global Franchise Head, where he directed the commercial strategy for one of the company’s largest business franchises. Mr. Sims will lead the commercial strategy and […] The post Candel Therapeutics Designates Mark Sims as CCO appeared first on ExecEdge.